106-gene cfDNA assay for hematologic malignancies

• Detects SNVs, Indels, CNVs, and rearrangements

• Designed to predict responses to immunotherapies and targeted therapies

• Measures critical biomarkers in B-cell malignancies

• Multiple sample types acceptable for testing

PredicineHEME Assay

Features and benefits

Low Input of Predicine Assays

Low sample input ≥0.4mL

High Sensitivity Predicine

Ultra-high sensitivity ≥0.05%

Specimen flexibility

Actionable results and data interpretation

Sample types

Whole blood
Bone marrow aspirate 

Sample requirements

10ml whole blood
4ml plasma (down to 0.4ml)
0.4ml bone marrow aspirate

Turnaround time

10 days

*PredicineHEME™ is for RUO.  

Characterize genomic footprint and monitor disease progression in blood cancers

PredicineHEME™ is a 106 gene assay that targets known mutations associated with B-cell malignancies including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma (MCL). The assay can help guide decisions for immunotherapy, targeted therapy and relevant clinical trials for blood cancers.  It is currently used in clinical research. 


PredicineHeme for Blood Cancers


PredicineATLAS workflow

Available in RUO and CLIA-validated assay


We offer pilot program grants to select biopharma and academic partners to empower translational research and clinical studies. To initiate a study, contact us via the form below.

Contact us

If you have any questions or need assistance, complete this form and we will respond within 24 hours.